Clinical Trials Using Avelumab

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are studying Avelumab. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-25 of 31
1 2 Next >

  • A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

    This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy, administered as first-line treatment, in patients with advanced renal cell carcinoma
    Location: 20 locations

  • A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

    This is a Phase 1b / 2 dose-optimization study to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of avelumab (MSB0010718C) in combination with other cancer immunotherapies in patients with locally advanced or metastatic solid tumors. The primary purpose is to assess the safety and early signs of efficacy of various avelumab combinations with other cancer immunotherapies, optimizing dosing regimens as appropriate, in a limited series of indications.
    Location: 15 locations

  • Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)

    This is a phase 3 randomized, placebo controlled study to evaluate the safety and anti-tumor activity of Avelumab in combination with standard of care chemoradiation (SoC CRT) versus SoC CRT alone in front-line treatment of patients with locally advanced head and neck cancer.
    Location: 15 locations

  • Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)

    This is a Phase 3, open-label, international, multi-center, efficacy, and safety study of avelumab in combination with and / or following platinum-based chemotherapy. Eligible patients must have previously untreated, histologically confirmed Stage III-IV epithelial ovarian (EOC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) and be candidates for platinum-based chemotherapy. The primary purpose of the study is to demonstrate if avelumab given as single agent in the maintenance setting following frontline chemotherapy or in combination with carboplatin / paclitaxel is superior to platinum-based chemotherapy alone followed by observation in this population of newly diagnosed ovarian cancer patients.
    Location: 13 locations

  • Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

    This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in subjects with selected tumor indications. New recruitment is open for all active cohorts. Active cohorts: Escalation revised dosing regimen cohort. Closed cohorts: Non-small cell lung cancer (NSCLC, first line), NSCLC (post-platinum), metastatic breast cancer (MBC), colorectal cancer (CRC), urothelial carcinoma (secondary), mesothelioma, gastric / GEJ cancer (first line switch maintenance and second line), and ovarian cancer (secondary and platinum refractory + liposomal doxorubicin), renal cell carcinoma (second line) melanoma and head, neck squamous cell carcinoma (HNSCC), castrate-resistant prostate cancer (CRPC), adrenocortical carcinoma (ACC) urothelial carcinoma (efficacy), gastric / gastroesophageal junction (GEJ) cancer (third line), renal cell carcinoma (RCC, first line) and escalation phase .
    Location: 11 locations

  • Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

    The purpose of this study is to demonstrate superiority of treatment with avelumab versus continuation of first-line chemotherapy.
    Location: 9 locations

  • Phase 1b / 2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer

    The purpose of this study is to determine the biologically active dose of entinostat, when given in combination with avelumab, that is safe and warrants further investigation. Additionally, this study will evaluate the effectiveness of entinostat in combination with avelumab at the determined dose in terms of progression free survival compared to avelumab plus placebo in patients with refractory or recurrent epithelial ovarian cancer.
    Location: 7 locations

  • Avelumab in Treating Patients with MSS, MSI-H, and POLE-Mutated Recurrent or Persistent Endometrial Cancer

    This phase II trial studies how well avelumab works in treating patients with microsatellite stable (MSS), high frequency microsatellite instability (MSI-H), and polymerase e (POLE)-mutated endometrial cancer that has spread to other places in the body or that does not go to remission despite treatment. Monoclonal antibodies, such as avelumab, may interfere with the ability of tumor cells to grow and spread.
    Location: 5 locations

  • A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)

    The main purpose of this study is to compare maintenance treatment with avelumab plus best supportive care (BSC) with BSC alone, to determine if avelumab has an effect on survival in patients with locally advanced or metastatic urothelial cancer that did not worsen during or following completion of first-line chemotherapy.
    Location: 5 locations

  • Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200)

    This is a multicenter, international, single-arm, open-label, Phase 2 trial to evaluate the efficacy and safety of avelumab in subjects with metastatic Merkel cell carcinoma (MCC).
    Location: 5 locations

  • Avelumab and Hypofractionated Radiation Therapy in Treating Patients with Transformed IDH Mutant Glioblastoma

    This phase II trial studies the best dose and side effect of avelumab and how well it works when given together with hypofractionated radiation therapy treating patients with transformed IDH mutant glioblastoma. Monoclonal antibodies, such as avelumab, may interfere with the ability of tumor cells to grow and spread. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving avelumab and hypofractionated radiation therapy may work better in treating patients with glioblastoma.
    Location: 4 locations

  • Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and / or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R / R DLBCL)

    Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by Phase 3), parallel-arm study of avelumab in combination with various agents for the treatment of Relapsed / Refractory (R / R) Diffuse Large B-Cell Lymphoma (DLBCL).
    Location: 3 locations

  • Avelumab in Treating Patients with Recurrent, Metastatic EBV-Related Nasopharyngeal Carcinoma

    This phase II trial studies how well avelumab works in treating patients with Epstein-Barr virus (EBV)-related nasopharyngeal carcinoma that has come back and has spread to other places in the body. Monoclonal antibodies, such as avelumab, may interfere with the ability of tumor cells to grow and spread.
    Location: 6 locations

  • Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R + / - T790M)

    This is a Phase 1 / 2 study of PF-06747775 as a single agent and in combination with other cancer treatments in patients with advanced EGFRm NSCLC. The overall clinical study consists of a Phase 1 single agent dose-escalation and expansion part to determine the RP2D of PF-06747775 single agent in patients with previously-treated EGFRm NSCLC followed by sequential evaluations of PF-06747775 at the RP2D in 3 different clinical scenarios as detailed below: - Cohort 1: Phase 2 evaluation of PF-06747775 as a single agent in previously untreated patients with advanced EGFRm NSCLC, - Cohort 2: Phase 1b single arm evaluation of PF-06747775 in combination with palbociclib (Cohort 2A) followed by Phase 2 randomized evaluation of PF 06747775 in combination with palbociclib vs PF-06747775 single agent (Cohort 2B) in previously-treated patients with EGFRm NSCLC with a secondary T790M mutation (del 19 and T790M or L858R and T790M), and - Cohort 3: Phase 1b evaluation of PF-06747775 in combination with avelumab in previously-treated patients with EGFRm NSCLC with a secondary T790M mutation (del 19 and T790M or L858R and T790M).
    Location: 5 locations

  • Fulvestrant with or without Palbociclib and Avelumab in Treating Patients with Hormone Receptor Positive, HER2 Negative Metastatic or Recurrent Breast Cancer That Cannot Be Removed by Surgery Previously Treated with CDK and Endocrine Therapy

    This randomized pilot phase II trial studies how well fulvestrant with or without palbociclib and avelumab works in treating patients with hormone receptor positive, HER2 negative breast cancer that has spread to other parts of the body or that has come back after a period of improvement and cannot be removed by surgery, and have been previously treated with CDK and endocrine therapy. Endocrine therapy with fulvestrant prevents growth of hormone receptor positive breast cancer by blocking stimulation of tumor cells by estrogen. Palbociclib is a drug that may stop tumor cells from growing by blocking activity of two closely related enzymes (proteins that help chemical reactions in the body occur), called cyclin dependent kinases 4 and 6 (CDK 4 / 6) which are known to promote tumor cell growth. Monoclonal antibodies, such as avelumab, may help the immune system in detecting and fighting tumor cells. Giving fulvestrant with or without palbociclib and avelumab may work better in treating patients with breast cancer.
    Location: 2 locations

  • Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer

    This is a Phase 1 / 1b, open-label, multicenter, dose-escalation and dose expansion trial to evaluate the safety, efficacy, PK and PD of defactinib (VS-6063) in combination with avelumab in epithelial ovarian cancer.
    Location: 4 locations

  • Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)

    The purpose of this study is to evaluate the safety and efficacy of avelumab when combined with either crizotinib or PF-06463922.
    Location: 2 locations

  • Avelumab and Stereotactic Body Radiation Therapy in Treating Patients with Non-responsive or Progressive Stage IV Non-small Cell Lung Cancer Previously Treated with PD-1 Inhibitor

    This pilot early phase I trial studies how well avelumab and stereotactic body radiation therapy (stereotactic ablative radiotherapy) work in treating patients with stage IV non-small cell lung cancer previously treated with a PD-1 inhibitor that is non-responsive or growing, spreading, or getting worse. Monoclonal antibodies, such as avelumab, may interfere with the ability of tumor cells to grow and spread. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Giving avelumab and stereotactic body radiation therapy may kill more tumor cells and work better in treating patients with non-small cell lung cancer.
    Location: University of California Davis Comprehensive Cancer Center, Sacramento, California

  • Avelumab in Treating Patients with Advanced Thymoma or Thymic Carcinoma That Cannot Be Removed by Surgery

    This pilot phase II trial studies the side effects and how well avelumab works in treating patients with thymoma or thymic carcinoma that has spread to other places in the body and cannot be removed by surgery. Monoclonal antibodies, such as avelumab may block tumor growth in different ways by targeting certain cells.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Standard of Care Chemotherapy and Bevacizumab with or without Ad-CEA Vaccine and Avelumab in Treating Patients with Metastatic Colorectal Cancer

    This randomized phase II trial studies how well standard of care chemotherapy and bevacizumab with or without adenoviral vector Ad5-CEA(6D) (Ad-CEA) vaccine and avelumab works in treating patients with colorectal cancer that has spread to other places in the body. Drugs used in standard of care chemotherapy, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab and avelumab, may interfere with the ability of tumor cells to grow and spread. Vaccines may help the body build an effective immune response to kill tumor cells. Giving standard of care chemotherapy and bevacizumab with avelumab and Ad-CEA vaccine may work better in treating patients with metastatic colorectal cancer.
    Location: 2 locations

  • Avelumab and Stereotactic Body Radiation Therapy in Treating Patients with Stage I Non-small Cell Lung Cancer

    This phase I / II studies the side effects of stereotactic body radiation therapy and avelumab in treating patients with stage I non-small cell lung cancer. Monoclonal antibodies, such as avelumab, may block tumor growth in different ways by targeting certain cells. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Giving avelumab and stereotactic body radiation therapy together may work better in treating patients with non-small cell lung cancer.
    Location: University of California San Diego, San Diego, California

  • Avelumab in Treating Patients with Recurrent or Progressive Osteosarcoma

    This phase II trial studies how well avelumab works in treating patients with osteosarcoma that has come back or is growing, spreading, or getting worse. Monoclonal antibodies, such as avelumab, may interfere with the ability of tumor cells to grow and spread.
    Location: St. Jude Children's Research Hospital, Memphis, Tennessee

  • Avelumab in Treating Patients with Advanced or Metastatic Small Intestine Cancer

    This pilot phase II trial studies the side effects of avelumab and how well it works in treating patients with small intestine cancer that has spread to other places in the body or usually cannot be cured or controlled with treatment. Monoclonal antibodies, such as avelumab, may interfere with the ability of tumor cells to grow and spread.
    Location: Vanderbilt University / Ingram Cancer Center, Nashville, Tennessee

  • A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12)

    The study consists of 2 parts: Dose Escalation phase (Part A) and Expansion phase (Part B). The dose escalation phase will evaluate the safety, tolerability, and PK of avelumab in combination with NHS-IL12 in subjects with locally advanced, unresectable, or metastatic solid tumors. Expansion phase will assess the safety and clinical activity of the combination regimen in selected tumor types. In Expansion phase subjects who have completed the combination treatment of avelumab at a given dose level of NHS-IL12, a safety review will be performed by the Safety monitoring committee in order to make a decision on the next dose level. Successive cohorts of 3 to 6 subjects will be treated with escalating doses of NHS-IL12 with avelumab intravenous (IV).
    Location: 2 locations

  • Avelumab and Azacitidine in Treating Patients with Refractory or Relapsed Acute Myeloid Leukemia

    This phase Ib / II trial studies the best dose and side effects of avelumab when given together with azacitidine and to see how well they work in treating patients with acute myeloid leukemia that is not responding to treatment or has come back. Monoclonal antibodies, such as avelumab, may interfere with the ability of cancer cells to grow and spread. Azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving avelumab and azacitidine may work better in treating patients with acute myeloid leukemia.
    Location: M D Anderson Cancer Center, Houston, Texas


1 2 Next >